Business News / Markets

Dicerna Pharmaceuticals Doses First Patient with DCR-PHXC in Phase 1 Clinical Trial

Dicerna Pharmaceuticals (DRNA) said Wednesday it has dosed the first primary hyperoxaluria (PH) patient with DCR-PHXC in a phase 1 clinical trial.

DCR-PHXC is an investigational GalXC product candidate in development for the treatment of all forms of PH, a family of severe, rare, inherited disorders of the liver that often result in kidney failure.

The company also announced that the US Food and Drug Administration (FDA) granted orphan drug designation to DCR-PHXC for the treatment of PH. Dicerna expects to have clinical proof-of-concept data from the PHYOX trial in the second half of 2018.